Monte Rosa Therapeutics (NASDAQ:GLUE - Get Free Report)'s stock had its "sell (d)" rating reiterated by research analysts at Weiss Ratings in a report released on Wednesday,Weiss Ratings reports.
Monte Rosa Therapeutics Stock Performance
Shares of NASDAQ:GLUE opened at $7.71 on Wednesday. The company has a market capitalization of $476.16 million, a P/E ratio of 21.42 and a beta of 1.54. Monte Rosa Therapeutics has a fifty-two week low of $3.50 and a fifty-two week high of $12.40. The company's 50-day moving average is $5.53 and its 200 day moving average is $4.99.
Monte Rosa Therapeutics (NASDAQ:GLUE - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.16. Monte Rosa Therapeutics had a net margin of 13.58% and a return on equity of 9.95%. The business had revenue of $23.19 million for the quarter, compared to analyst estimates of $7.23 million. As a group, research analysts predict that Monte Rosa Therapeutics will post -1.49 earnings per share for the current year.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in the company. BVF Inc. IL lifted its position in shares of Monte Rosa Therapeutics by 104.7% during the 1st quarter. BVF Inc. IL now owns 5,660,132 shares of the company's stock valued at $26,263,000 after buying an additional 2,895,661 shares during the last quarter. AQR Capital Management LLC raised its stake in Monte Rosa Therapeutics by 459.4% in the 2nd quarter. AQR Capital Management LLC now owns 1,283,942 shares of the company's stock valued at $5,791,000 after acquiring an additional 1,054,406 shares during the period. Geode Capital Management LLC increased its stake in shares of Monte Rosa Therapeutics by 12.0% in the second quarter. Geode Capital Management LLC now owns 1,124,160 shares of the company's stock worth $5,071,000 after purchasing an additional 120,098 shares in the last quarter. Parkwood LLC increased its stake in shares of Monte Rosa Therapeutics by 119.2% in the first quarter. Parkwood LLC now owns 708,000 shares of the company's stock worth $3,285,000 after purchasing an additional 385,000 shares in the last quarter. Finally, Marshall Wace LLP boosted its holdings in Monte Rosa Therapeutics by 20.0% in the 2nd quarter. Marshall Wace LLP now owns 446,080 shares of the company's stock worth $2,012,000 after buying an additional 74,342 shares during the period. Hedge funds and other institutional investors own 79.96% of the company's stock.
About Monte Rosa Therapeutics
(
Get Free Report)
Monte Rosa Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Monte Rosa Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Monte Rosa Therapeutics wasn't on the list.
While Monte Rosa Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
